

## Targinta presents new preclinical data on TARG10 at the AACR Annual Meeting

**The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), presents new preclinical data on TARG10 at the AACR Annual Meeting (April 8-13) in a poster titled "The integrin  $\alpha 10\beta 1$  antibody TARG10 reduces tumor growth and metastasis of triple-negative breast cancer".**

Targinta develops first-in-class tumor-targeting antibodies and ADCs against the novel and patent protected cancer target integrin  $\alpha 10\beta 1$ . Integrin  $\alpha 10\beta 1$  is a cell adhesion receptor that has been shown to be important for the ability of cancer cells to grow, proliferate and to metastasize. It is highly expressed in triple-negative breast cancer (TNBC) but not in normal breast tissue.

The new data presented at AACR includes target expression in different breast cancer cell lines and the demonstration of a positive correlation with TNBC aggressiveness. Further, it has been demonstrated that the integrin  $\alpha 10$ -antibody TARG10 reduces adhesion, migration, and proliferation of TNBC cells *in vitro*. This effect was associated with almost complete prevention of metastasis in a TNBC tumor model. In addition, data on pharmaceutical and pharmacokinetic properties are presented confirming excellent developability properties including pharmaceutical stability, low immunogenicity and a long terminal half-life in preclinical models.

*"The new data on TARG10 gives strong support for the continued development of the candidate and for its potential to become a novel therapy for patients with triple-negative breast cancer. The observed effects on metastasis are truly impressive and a great validation of the mechanism of action of TARG10 and of our unique cancer target integrin  $\alpha 10\beta 1$  ", says Per Norlén, CEO at Targinta.*

The poster will be presented by Katarzyna Masoumi, Project Director at Targinta AB, at 9 a.m. CDT (16.00 CEST) on April 12, 2022.

**For further information please contact:**

Per Norlén, CEO Targinta AB

Email: [per.norlen@targinta.se](mailto:per.norlen@targinta.se)

Phone: +46 46 275 65 00

---

## About Targinta

Targinta is a preclinical stage oncology biotech company, developing first-in-class tumor-targeting antibodies and antibody-drug conjugates (ADCs) for aggressive cancers based on the in-house discovery of the novel patent-protected cancer target integrin  $\alpha 10\beta 1$ . The pipeline includes TARG10, a function-blocking intergrin  $\alpha 10$ -antibody that is being developed to prevent metastasis, and TARG9, an intergrin  $\alpha 10$ -ADC that is armed with a powerful toxin that selectively kills tumor cells. Targinta is a wholly owned subsidiary of Xintela AB (publ) and is headquartered in Lund, Sweden. For more information, please visit [www.targinta.se](http://www.targinta.se).

---

## About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin  $\alpha 10\beta 1$  which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is now entering a clinical development phase for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin  $\alpha 10\beta 1$  (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se).

---

## Attachments

[Targinta presents new preclinical data on TARG10 at the AACR Annual Meeting](#)